In this scenario, however, it is useful to acknowledge that in vivo studies on murine models and clinical trials on the treatment with bevacizumab (a monoclonal antibody targeting VEGF) have led to the observations that some aggressive and resistant cellular clones (able to form pseudopods and to migrate) are selected by the therapy, giving rise to tumor relapse. The gene discussed is VEGFA; the disease is neoplasm.